Kornimate/medical-research-clean huggingface dataset:
prospective study of fibrosis in the lung endpoints (profile - central england)

Conditions: Idiopathic Pulmonary Fibrosis

Summary: the overall aim of this study is to develop a test that predicts the prognosis of ipf (idiopathic pulmonary fibrosis) and which could be used to determine whether new treatments for ipf are likely to work.

the overall objectives of this study are * discover and validate novel biomarkers and gene expression profiles for use in subsequent intervention studies in patients with ipf * to prospectively validate a panel of previously published biomarkers in patients with well characterized idiopathic fibrosing lung disease * investigate genetic associations and epigenetic modifications which affect disease severity and progression * prospectively evaluate longitudinal disease behaviour in patients with ipf and nsip with a view to developing composite clinical end-points for subsequent use in intervention studies in patients with ipf biomarkers that can be used for the following purposes will be identified: * identify patients (diagnostic)(e.g. discriminate between health and disease) * correlate with disease severity (extent of disease, staging of disease) * predict clinical progression (prognostic)(stable vs progressive disease) * track response to therapy (therapeutic response)- predict response to known efficacious treatments \& correlates with changes in clinical endpoints/mortality/quality of life * predict risk of exacerbations (could be used to prevent exacerbations or reduce their severity) * correlate with complications and/or comorbidities (e.g. biomarkers of pulmonary arterial hypertension, gastro oesophageal reflux in ipf, etc)

Eligibility criteria:
inclusion criteria: a diagnosis of ipf using the consensus criteria (32)and non specific interstitial pneumonia. * between the age group 18-85 years. * sub classified into mild (tlco\>60), moderate (tlco 40-60), severe (tlco\<40). * people who volunteer to undergo a bronchoscopy for research exclusion criteria: * people who do not have ipf/nsip (i.e. hypersensitivity pneumonitis, sarcoidosis) * people who cannot give informed consent. * people who are being considered for bronchoscopy, any contra-indication to undergoing this procedure as set out in the british thoracic society guidelines (thorax 2001; 56: suppl i: i1-i21). these will be part of the study but not undergo the broncho alveolar lavage.

Keywords: idiopathic pulmonary fibrosis ipf lung fibrosis biomarkers
evaluating the association between pericardial fat and coronary heart disease - ancillary to mesa

Conditions: Coronary Disease

Summary: coronary heart disease (chd) is the leading cause of death in the united states. one common risk factor for chd is obesity. the presence of certain types of fat over others is more commonly associated with the development of chd. this study will use data from a previous study to examine the association between pericardial fat, a type of fat that surrounds the heart, and chd.

chd is caused by a narrowing of the small blood vessels that supply blood and oxygen to the heart. it usually results from atherosclerosis, a condition in which deposits of fat, cholesterol, and other substances build up along the inner walls of arteries. risk factors for chd include tobacco use, high blood pressure, diabetes, and obesity. visceral fat, the type of fat found in the abdomen and surrounding vital organs, is considered a greater risk factor for chd than subcutaneous fat, the type of fat found directly below the skin. pericardial fat, the fat surrounding the heart, is similar to visceral fat, and may be particularly damaging because of its lipotoxicity effects and its ability to trigger inflammation in the coronary arteries. increased amounts of pericardial fat may therefore accelerate the development of atherosclerosis and chd. the purpose of this study is to evaluate the relationship between pericardial fat and the development of chd. this study will use previously collected data from participants in the multi-ethnic study of atherosclerosis (mesa) study, a study that examined characteristics of the subclinical, or the early stages of, cardiovascular disease in individuals. there will be no study visits specifically for this study. participants' study data and computed tomography (ct) scans will be analyzed to determine the following: 1) the presence of pericardial fat and subclinical chd at study entry; 2) changes in pericardial fat levels and plaque formation; and 3) the presence of pericardial fat and chd at a 6-year follow-up visit.

Eligibility criteria:
inclusion criteria: * participant in the mesa study * had a baseline and 6-year follow-up ct scan as part of the mesa study exclusion criteria: * participant did not have a baseline or 6 year follow-up ct in the mesa study

Keywords: coronary heart disease
apitox, honeybee toxin for pain and inflammation of osteoarthritis

Conditions: Osteoarthritis of the Knee

Summary: the study will identify the efficacy of apitox, purified honeybee toxin, in 330 patients with diagnosed osteoarthritis of the knee. the subjects will be evaluated for relief of pain using western ontario and mcmaster osteoarthritis index (womac) and physician and patient global assessments and primary efficacy measure of relief of pain and inflammation over a 12 week treatment period after randomization into the trial. secondary efficacy is improvement of mobility treatment effect will be compared in a 2-1 apitox vs active control

feasibility and site selection has been completed in the us and india

Eligibility criteria:
inclusion criteria: * osteoarthritis of one or both knees * on stable nsaid or none due to intolerance * women either post menopausal or on stable birth control * no clinically significant disease or or abnormal laboratory values * signed informed consent, communicate effectively, understand and comply with all study requirements exclusion criteria: * serious or unstable medical or psychological condition * known sensitivity to honeybee venom, histamine or lidocaine * history of asthma * any clinically significant ecg abnormalities * any clinically significant laboratory values oor * history of drug or alcohol abuse * history of joint injury and forms of inflammatory arthritis

Keywords: honeybee toxin apitox pain inflammation osteoarthritis apitoxin
pharmacokinetics, safety, and tolerability of methylnaltrexone in volunteers with impaired hepatic function

Conditions: Liver Dysfunction

Summary: this is a multicenter, non-randomized, single-dose, parallel-group study. each subject will receive a subcutaneous dose of mntx. eight subjects with normal hepatic function and eight subjects from each classification of hepatic impairment will be enrolled. plasma samples will be collected before and at specified intervals after dosing and the concentration of mntx will be analyzed.


Eligibility criteria:
inclusion criteria: 1. males and females between the ages of 18-80 years 2. body weight greater than 100 lbs and bmi between 18-38 3. liver values that are abnormal must not be clinically relevant as judged by the investigator. liver enzyme and bilirubin must be less than 5 times the upper normal of reference range and may be repeated under fed conditions if abnormal. stable hepatitis patients as well as cirrhosis patients of either etiology. exclusion criteria: 1. history of current alcohol abuse with less than 1 year abstinence 2. conditions possibly affecting drug absorption, e.g. gastrectomy or clinically significant diabetic gastroenteropathy. 3. currently pregnant or nursing 4. methadone use.
the impact of pain neuroscience education on physical therapy student's knowledge, attitudes, beliefs, and behaviours towards pain

Conditions: Healthy Subjects

Summary: this study investigates the effect of pain neuroscience education (pne) on pain knowledge, attitudes, and beliefs among undergraduate physiotherapy students in jordan

physiotherapy students at the hashemite university will be randomly assigned into either pain neuroscience education or control lectures groups. both groups will receive a 70-min didactic group-lecture. the control group will receive education about red-flags which are special screening questions for serious pathology. the red-flags education will discuss tissue pathology and triage for back pain classification. neurophysiology and the biopsychosocial mode will not be discussed. the intervention group will receive a pne lecture

Eligibility criteria:
inclusion criteria: * physiotherapy undergraduate students at the hashemite university exclusion criteria: * previous formal pain education * enrolled in a clinical practice module

Keywords: pain physiotherapy students attitudes education
confirmatory study of mt-2412 in japanese patients with type 2 diabetes (add-on study of teneligliptin)

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to evaluate the efficacy and safety of co-administration of canagliflozin (ta-7284) and teneligliptin (mp-513) once daily for 24 weeks in japanese patients with type 2 diabetes mellitus who are receiving treatment with canagliflozin and have inadequate glycemic control.


Eligibility criteria:
inclusion criteria: * men or women who are 20 - 75 years old * hba1c of ≥7.0% and \<10.5% * fpg of ≤ 270 mg/dl * patients who are under dietary management and taking therapeutic exercise for diabetes over 8 weeks before run-in period exclusion criteria: * patients with type i diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes * patients with serious diabetic complications * patients with hereditary glucose-galactose malabsorption or primary renal glucosuria * patients with class iii/iv heart failure symptoms according to new york heart association (nyha) functional classification * patients with severe hepatic disorder or severe renal disorder.

Keywords: mt-2412 mp-513 ta-7284 teneligliptin canagliflozin
developmental of clinical prediction rule for females responding to proximal control exercises

Conditions: Patellofemoral Pain Syndrome Clinical Prediction Rule

Summary: the aim of study is to investigate the effect of body mass index (bmi), age, duration of symptoms, pain severity and knee angle valgus on patient̕̕s response to proximal control exercises.

patellofemoral pain syndrome (pfps) is recognized as one of the most common lower-extremity disorders encountered by orthopaedic physical therapists. females were 2.23 times more likely to develop pfps than males. various authors have suggested that hip weakness may be an impairment associated with pfps, because poor hip control may lead to abnormal lower extremity or patellofemoral motions. clinical prediction rules (cprs) are tools designed to improve decision making in clinical practice by assisting practitioners in making a particular diagnosis, establishing a prognosis, or matching patients to optimal interventions.

Eligibility criteria:
inclusion criteria: * age 18 to 35 years. * anterior or retropatellar knee pain of non-traumatic origin that was greater than six weeks duration and provoked by at least two predefined activities (prolonged sitting or kneeling, squatting, jogging or running, hopping, jumping, or stair walking). * pain on palpation of the patellar facets, or with step down from a 15 cm step, or double leg squat. exclusion criteria: 1. concomitant injury or pathology of other knee structures. 2. previous knee surgery. 3. patellofemoral instability (history of sublaxation or dislocation; positive apprehension test). 4. knee joint effusion. 5. osgood-schlatter's. 6. hip or lumbar spine pain (local or referred). 7. physiotherapy within previous year; prior foot orthoses treatment or use of anti inflammatories or corticosteroids.

Keywords: clinical predicton rule proximal control exercises
a pilot study to evaluate purewick for nocturia

Conditions: Nocturia

Summary: this is a single-center prospective pilot study of purewick used as a management for nocturia and reduction of nighttime falls associated with going to the bathroom. subjects are followed up to 3 months after the intervention. as a pilot study, it is expected that a 3-month follow-up will adequately capture urinary and sleep outcomes data and any adverse events related or unrelated to the study device.

nocturia is a highly prevalent condition among older adults, significantly affecting the quality of life as well as putting them at an increased risk of falls and fractures. in those 65 and older, accidental falls are identified as the leading cause of injury and death. the chance of falling increases from 30% to 50% with age greater than 85 years. a study identified that in 1508 ambulatory men and women, nighttime urination of 2 times at night is associated with increased risk of falls (or=1.84, 95% ci 1.05-3.22), with significantly higher risks when it increased to 3 or more times at night (or=2.15, ci 95% -1.04-4.44). incontinence management that reduces the need to get out of bed will lead to reduced risk of falls and unintentional injury fatalities. the purewick urine collection system is intended for non-invasive urine output management. it pulls urine through tubing that is connected to a collection canister for proper disposal. it is designed to be used by patients, caregivers, or healthcare professionals in both home environments and professional care facilities. the purewick system allows individuals to void while still in bed, demonstrating the potential to reduce the risks of falls associated with nighttime voids in men and women with nocturia. we hypothesize that this will also improve sleep quality and overall quality of life.

Eligibility criteria:
inclusion criteria: * women aged 50 years or older. * experiences 2 or more voids per night as assessed on a 3-day bladder diary. exclusion criteria: * compromised skin integrity in the perineal area (e.g., ulcers, open wounds, etc.). * neurological impairment or psychiatric disorder preventing proper understanding of consent. * unable to operate the purewick system. * unable to complete required questionnaires and diaries. * investigator deems subject as unsuitable for enrollment.
safety and feasibility of a low carbohydrate diet in children with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: good glycemic control in individuals with type 1 diabetes (t1d), has been proven to reduce the risk of diabetes-related complications. despite technological advances such as the use of insulin delivery devices and continuous glucose monitoring, the average glycemic control in t1d is poor. though dietary management plays a major role in the overall management of t1d, and it is often classified as the most challenging aspect of treatment, the 2019 standards of medical care in diabetes for children and adolescents do not clearly address dietary management. as carbohydrate is the macronutrient with the greatest impact on blood glucose, it is reasonable to suggest that carbohydrate reduction will minimize postprandial glucose excursions and improve diabetes control. for this reason, low carbohydrate diets (lcd) have gained popularity, and observational studies report positive glycemic outcomes. however, to date, scientific evidence from randomized trials on the impact of lcd in children with t1d is lacking. thus, the over-arching goal of this pilot study is to evaluate the feasibility and safety of a low carbohydrate diet in children with t1d, and as an exploratory aim, we will evaluate the efficacy of lcd on glycemic control.

the investigators aim to study 40 subjects ages 5-11 with t1d to evaluate the feasibility of lcd. participants will be asked to attend a total of 5 visits (4 in person and 1 phone visit) during the 6 month-duration of the study. participants will be randomized to an intervention group with a lcd (50% of carbohydrate recommended daily allowance) vs. the standard diet. during the screening visit, participants will be assessed by a dietitian to categorize their existing dietary regimen before randomization to either the lcd or the standard diet. in addition, participant's insulin regimen (either pump settings or multiple dose insulin injection therapy) will be reviewed for insulin dose adjustments as needed over a 2 week-period.

Eligibility criteria:
inclusion criteria: * patients 5-11 years of age, with history of type 1 diabetes for longer than 2 years, * no carbohydrate restrictions at the time of recruitment. * no medications that could affect appetite * regular attendance at the clinic (3-4 times per year), * glycated hemoglobin (hba1c) \<10%. exclusion criteria: * impaired renal or liver function, * chronic seizures or global developmental delay, * diagnosed with adhd and/or on adhd medications * use of drugs other than insulin affecting glucose metabolism * severe eczema * celiac disease
qualitative research for stage 4 liver cancer patients and their caregivers

Conditions: Stage 4 Liver Cancer

Summary: this is opinion based, experiential research and is not a drug trial.


Eligibility criteria:
inclusion criteria: * stage 4 liver cancer patients and caregivers exclusion criteria: * loved ones passed away

Keywords: patients or caregivers for caregivers, loved one must still be living
maxillary and mandibular arch response to rme: a multicentric randomized controlled trial

Conditions: Posterior Crossbite

Summary: posterior crossbite is a common clinical condition often associated with transverse maxillary deficiency and functional mandibular shift. this frequent malocclusion is not self-correcting and can lead to the development of craniofacial asymmetries and mandibular dysfunction. the aim of the current study was to evaluate maxillary and mandibular arch widths' response to rme when it is anchored to the upper second deciduous molars or to the upper first permanent molars and to create a decision-making protocol for rme therapy in mixed-dentition patients.

the effects of rapid maxillary expansion (rme) on the maxillary complex have been highly investigated,4 reporting a maximum maxillary intermolar and intercanine width increase of 6.7 mm and 5.3 mm,5 respectively, when rme is banded on upper first permanent molars. literature also reported cases of periodontal and endodontic damage on rme anchoring teeth; therefore, some authors have suggested banding rme on primary teeth and reporting also different mean intermolar (3.6-4.1 mm) and intercanine width increases (5-5.9 mm). few studies have investigated the changes in molar dental tipping and inclinations (on average from 3° up to 16.7°) following rme but comprised difficult (ie, barium sulfate solution) and more invasive examinations such as computed tomography and cone beam computed tomography (cbct) few articles concerning the indirect effects on mandibular arch following rme reported a low but statistically significant increase of lower intermolar (0.66-0.97 mm) and intercanine width (0.9 mm). since no studies in the literature have analyzed the differences in permanent vs primary molars as anchoring teeth for rme, the decision to band the permanent deciduous molars did not follow a clinical protocol, but an individual decision was made for each patient based on clinician experience.

Eligibility criteria:
inclusion criteria: * patients in mixed dentition * unilateral posterior crossbite at least of the first permanent molar * upper deciduous second molars available as rme anchoring teeth exclusion criteria: primary exclusion criteria * previous orthodontic treatment * hypodontia in any quadrant excluding third molars * inadequate oral hygiene * temporomandibular joint disorders * craniofacial abnormalities * secondary exclusion criteria * lack of records * need for lingual arch * lack of consensus * need for other orthodontic treatment during rapid maxillary expansion
patient education in northtrondelag hospital trust

Conditions: Diabetes Mellitus

Summary: the purpose of this randomised open study is to examine the effect of self-management program for diabetes patients.

the primary aim in this study is hba1c in addition to secondary aims like quality of life and coping.

Eligibility criteria:
inclusion criteria: * diagnosed with icpc-2, code t89 - diabetes dependent on insulin and t90 diabetes not dependent on insulin exclusion criteria: * diagnosed with icpc-2, code t89 - diabetes mellitus juvenile and diabetes i * attended self-management program previous 12 months

Keywords: patient education as a topic self-management program health promotion self efficacy quality of life
low-dose chemotherapy combine with tyrosine kinase inhibitor to treat ph+ acute lymphoblastic leukemia patients

Conditions: ph+ Acute Lymphoblastic Leukemia

Summary: the aim of our study is to improve the major molecular remission(mmr) rate and reduce the cost to treat ph(+) acute lymphoblastic leukemia (all) by adjusting chemotherapy regimens and the dosage of tyrosine kinase inhibitor (tki). lower the classification of chemotherapy drugs, lower the side effect brought by which this would be a grateful news for the patients once this regimens gain a successful result, which is also the final aim of our efforts.

the investigators new therapy regimens: the investigators use dexamethasone 10mg/d(d3-d7) as pre-processing therapy, dasatinib 100mg (d1-d84) plus prednisone 60mg/m2 (d1-24), reduce to d32, as inductive treatment after inductive treatment, if the patient get major molecular remission, patient will get to consolidation therapy, that is methotrexate (mtx) 3g/m2 d1, if not, this patient would be excluded from our trail. after consolidation therapy, if the patient have matched bone marrow donor, the investigators will suggest the patient receipting allogens-stem cell transplantation, otherwise, autogens stem cell transplantation can also be considered once the patient have no applicable bone marrow donor. on the other side, if the patient still not get mmr after this two cycle, maybe the patient can try car-t, or other chemotherapy regimens.

Eligibility criteria:
inclusion criteria: 1. get signed the informed consent of patients and family members 2. age ≥ 18 one full year of life 3. confirm the ph + all at molecular biology level 4. normal heart and lungs function 5. normal liver and kidney function exclusion criteria: 1. leukemia in the nervous system 2. recurrent patients 3. allergies associated with any drug in our research 4. at the same time with other organs' malignant tumours 5. participating in other clinical researches at the same time
clinical research of h3f3ak27m in spinal glioma and its impact on tmz chemoradiotherapy

Conditions: Spinal Tumor

Summary: h3f3ak27m may be a feature of primary spinal cord glioma and affect the outcome and prognosis of tmz chemoradiotherapy.


Eligibility criteria:
inclusion criteria: * surgical treatment and pathological confirmation of spinal glioma in our department and is the first case without any treatment before operation. exclusion criteria: * the tumor is recurrent or has been treated before operation.

Keywords: h3f3ak27m
treatment of patients with social anxiety disorder

Conditions: Social Phobia

Summary: gw876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with socad experience in social situations.


Eligibility criteria:
inclusion criteria: * are diagnosed with generalized social anxiety disorder/social phobia. exclusion criteria: * have a diagnosis of major depressive disorder * have a history of schizophrenia, schizoaffective disorder, or bipolar disorder.

Keywords: safety outpatients with a diagnosis of social anxiety disorder (socad). effectiveness